Cancer treatment just got faster: FDA approves Genentech’s Tecentriq Hybreza for quick 7-minute injection
The U.S. Food and Drug Administration (FDA) has granted approval for Tecentriq Hybreza, the first and only PD-(L)1 inhibitor for subcutaneous injection, developed by Genentech, a member of the Roche Group. This new formulation offers patients a quicker and more flexible cancer treatment option compared to the standard intravenous (IV) infusion. Tecentriq Hybreza is a […]